id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0117-0006,FDA,FDA-2011-E-0117,Determination of Regulatory Review Period for Purposes of Patent Extension: PRADAXA,Notice,Determinations,2012-05-03T04:00:00Z,2012,5,2012-05-03T04:00:00Z,2012-07-03T03:59:59Z,2014-12-29T18:20:37Z,2012-10712,0,0,090000648100432a
FDA-2011-E-0117-0005,FDA,FDA-2011-E-0117,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-04-18T04:00:00Z,2012,4,2012-04-18T04:00:00Z,,2024-03-13T11:56:43Z,,0,0,0900006480ff33a7
FDA-2011-E-0117-0004,FDA,FDA-2011-E-0117,Letter to U. S. Patent & Trademark Office,Other,Letter(s),2012-01-10T05:00:00Z,2012,1,2012-01-10T05:00:00Z,,2024-03-13T12:34:44Z,,0,0,0900006480f91f57